Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project
- PMID: 29923027
- PMCID: PMC6242792
- DOI: 10.1007/s13181-018-0668-2
Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project
Abstract
Introduction: Many new psychoactive substances (NPS) introduced as recreational drugs have been associated with severe intoxication and death.
Methods: Blood and/or urine samples were collected from intoxicated patients treated at Swedish hospitals that participated in the STRIDA project, a nationawide effort to address the growing problem of NPS. In patients undergoing evaluation for drug overdose, α-PBP was identified using liquid chromatography-mass spectrometry. Demographic and clinical data were collected during Poisons Information Centre consultations and retrieved from medical records.
Results: From April 2013 to November 2015, 43 patients tested positive for α-PBP. However, α-PBP was never specifically mentioned during consultation but only confirmed analytically. The α-PBP concentrations ranged 2.0-13,200 ng/mL in urine and 2.0-440 ng/mL in serum. The patients were aged 19-57 (mean 34) years, 81% were men, and 73% were known drug addicts. All cases except 1 also involved other NPS and/or classical drugs. MDPV, α-PVP, and other pyrovalerone analogues were the most common other NPS (31 cases; 72%). CNS depressants were detected in 28 cases (65%), with benzodiazepines (16 cases) being most frequent. Main clinical characteristics were agitation/anxiety (59%), tachycardia (54%), and hypertension (37%), and 14 patients (33%) required monitoring in the intensive care unit of which 8 were graded as severe intoxications. No fatalities were reported.
Conclusion: Patients with intoxication from α-PBP resembled those by NPS cathinones MDPV and α-PVP. As patients never specifically declared α-PBP intake and poly-drug intoxication was common, they may have been unaware of the actual substance taken.
Keywords: Cathinone; Intoxications; NPS; New psychoactive substances; α-PBP.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures
References
-
- EMCDDA. EU drug markets report 2016—in-depth analysis. 2016. Available at: http://www.emcdda.europa.eu/system/files/publications/2373/TD0216072ENN.PDF.
-
- EMCDDA. European Drug Report 2017: trends and developments. 2017. Available at: http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf.
-
- UNODC. World Drug Report 2017—market analysis of synthetic drugs. 2017. Available at: https://www.unodc.org/wdr2017/field/Booklet_4_ATSNPS.pdf.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous